Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nortran Pharmaceutical -NRT.V -- Ignore unavailable to you. Want to Upgrade?

To: Bart Hoenes who wrote (1082)	5/7/1999 3:16:00 PM
From: RBMac	Read Replies (2) \| Respond to of 1185

Nortran Pharmaceuticals Inc - Maedel says be patient with Nortran Nortran Pharmaceuticals Inc NRT Shares issued 27,673,299 1999-04-26 close $0.93 Monday Apr 26 1999 Neil Maedel, writing in the April 26, 1999, edition of Maedel's Mini-Cap Analyst, says he is holding his position in Nortran Pharmaceuticals even though the market has expressed its disappointment that the highly anticipated licensing deal between the company and Hoffmann-La Roche has yet to materialize. The Swiss-based newsletter writer notes that the giant Swiss pharmaceutical firm "has extended a small token of its continuing interest in Nortran's anti-arrhythmia drug by making a $100,000 (U.S.) payment to extend its option on four Nortran compounds until June 15, 1999." Mr. Maedel admits this news is disappointing, but "companies such as Roche are not known for moving quickly." Nortran CEO Bob Rieder claims that discussions between the two firms are becoming more "involved," and Mr. Maedel concludes that the chances of the licensing deal coming to fruition "are very good." (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com